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Abstract: The patient, a 66-year-old woman, who has been under hemodialysis due to 
antineutrophil cytoplasm autoantibody (ANCA)-associated glomerulonephritis since 2003, 
was hospitalized because of cold sweating, general fatigue, and somnolence. Hypoglycemia 
(43 mg/dL) with markedly elevated insulin level (1410 µU/mL) and insulin antibody was found 
in her serum. She was diagnosed as having insulin autoimmune syndrome. She has not taken 
any medication that might cause insulin autoimmune syndrome. The possible association of 
ANCA-associated glomerulonephritis with insulin autoimmune syndrome is discussed.
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Although insulin autoimmune syndrome is a relatively rare cause of hypoglycemia, 
it is the third leading cause of spontaneous hypoglycemia in Japan and more than 200 
cases have been reported (Uchigata and Hirata 1999). This syndrome is characterized 
by hypoglycemic episodes, elevated insulin levels, and positive insulin antibodies in 
patients with no prior insulin administration (Uchigata and Hirata 1999). The cause is 
not fully understood, however, various drugs as well as other autoimmune disorders 
are considered to be involved with its development. Herein, we report the ﬁ  rst known 
case of insulin autoimmune syndrome due to antineutrophil cytoplasm autoantibody 
(ANCA)-associated glomerulonephritis, which developed during hemodialysis.
A 66-year-old woman experienced excessive sweating, general fatigue, and som-
nolence was transferred to our hospital for examinations. She had a history of ANCA-
associated glomerulonephritis for 5 years, and had been receiving corticosteroid and 
hemodialysis. The patient also had pneumothorax for the previous 3 years and multiple 
peptic ulcers for the previous 4 years. She had not regularly taken any medication or 
supplements, and had not received insulin therapy in the past. A physical examina-
tion revealed a well-nourished woman, whose consciousness level was II-10 (Japan 
Coma Scale). She was 148 cm tall and weighed 55 kg, and her body mass index was 
25 kg/m2. There was no edema in the extremities, and her skin was warm and moist. 
Blood pressure was 117/84 mmHg, heart rate was 96 and regular, and temperature 
was 36.4 °C. Her head, eyes, nose, and throat appeared to be normal, while the lungs 
were clear and a cardiac examination was normal. The abdomen was soft, without 
tenderness, organomegaly, or apparent masses.
Results of laboratory studies showed hematocrit at 34.9% and white blood cells 
at 15,940/µl (74% neutrophils, 16% lymphocytes, 6% monocytes, 0% eosinophils, 
0% basophils). Plasma glucose was 42 mg/dl, and insulin and C-peptide immunore-
activity were 1410 µU/m and 28.8 ng/mL, respectively (Fajan’s index, 24.3), while 
serum creatinine was 6.4 mg/dl and blood urea nitrogen 26 mg/dl. The calculated 
glomerular ﬁ  ltration rate was 4.83 mL/min. Serum sodium, potassium, and chloride 
were 140 mmol/l, 4.3 mmol/l, and 100 mmol/l, respectively. Results of liver function, Diabetes, Metabolic Syndrome and Obesity 2008:1 2
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creatine phosphokinase, chest X-ray, and electrocardiogram 
examinations were unremarkable, except for elevated alka-
line phosphatase at 489 U/L. C-reactive protein was 7.1 
mg/dL and perinuclear-ANCA was 70.5 U/mL. Rheumatoid 
factor and dsDNA antibody were negative. The patient had 
recurrent hypoglycemic bouts, therefore continuous glucose 
infusion was initiated. Computed tomography of the abdo-
men and pelvis, as well as ultrasound ﬁ  ndings were negative 
for insulinoma. Antibodies to insulin were detected (insulin 
binding ratio 92.6%, free insulin 1410 µU/ml). A Scatchard 
plot analysis revealed that the afﬁ  nity of the antibodies was 
low and their binding activity high, which are common char-
acteristics of anti-insulin autoantibodies observed in insulin 
autoimmune syndrome (Eguchi 1989; Eguchi et al 1994; 
Furukawa et al 2006). Serum levels of thyroid hormone, 
adrenocorticotropic hormone, and glucocorticoid were nor-
mal. These ﬁ  ndings, including the symptoms and laboratory, 
endocrinological, and imaging results led us to a diagnosis 
of insulin autoimmune syndrome.
The association between sulfhydryl compounds and 
development of insulin autoimmune syndrome is well known, 
however, the present patient had not taken sulfhydryl com-
pounds, such as methimazole, α-mercaptopropionyl glycine, 
glutathione, or captopril, which cause the production of 
anti-insulin antibodies. Furthermore, the HLA-DRB1 *0406 
allele confers a high level of susceptibility to the syndrome 
(Uchigata et al 1992, 1993), however, HLA analysis could 
not be performed in the present case, since the patient died 
suddenly during hemodialysis.
To our knowledge, this is the ﬁ  rst case of insulin auto-
immune syndrome complicated with ANCA-associated 
glomerulonephritis to be reported following the initial 
description of the syndrome in 1970 (Hirata et al 1970). 
Although the present association with ANCA-associated 
glomerulonephritis may have been coincidental, patients 
with insulin autoimmune syndrome may also have a history 
of other autoimmune diseases, such as Graves’ disease, rheu-
matoid arthritis, or systemic lupus erythematous (Uchigata 
and Hirata 1999; Burch et al 1992). Therefore, it may be 
appropriate to include ANCA-associated glomerulonephritis 
in the group of underlying diseases of insulin autoimmune 
syndrome, though the relationship between ANCA and the 
anti-insulin antibody has not been clariﬁ  ed.
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